Xavier Leleu
Poitiers University Hospital · Service des maladies du sang, Hôpital Huriez, CHRU, Lille · CHRU de Lille
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Xavier Leleu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:04 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03683277 · IPD in RRMM Characterized With Genomic Abnormalities of Adverse PrognosticIntergroupe Francophone du Myelome · terminated · Multiple Myeloma, Relapsed and Refractory Multiple Myeloma, Genetic Condition · principal investigator
- N/ANCT02997813 · Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization StrategiesIntergroupe Francophone du Myelome · completed · Multiple Myeloma, Blood Stem Cell Transplant Failure · study chair
- Ph2NCT01745640 · Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)University Hospital, Lille · completed · Multiple Myeloma · principal investigator
- Ph2NCT01053949 · IFM2009-02-Pomalidomide and Dexamethasone Phase 2 MyelomaUniversity Hospital, Lille · completed · Multiple Myeloma · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:04 UTC. The ranking covers the 200 most relevant of 126 PubMed records, and a shared surname and initials can bring in a namesake. All 126 on PubMed
- 1,045 citationsRCR 36.3
- 960 citationsRCR 25.8
- 854 citationsRCR 35.4
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.N Engl J Med · 2019853 citationsRCR 33.9
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.Lancet Oncol · 2011753 citationsRCR 20.3
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.N Engl J Med · 2023749 citationsRCR 61.8
- 552 citationsRCR 82.9
- 536 citationsRCR 19.7
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.J Clin Oncol · 2015472 citationsRCR 12.9
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.N Engl J Med · 2018436 citationsRCR 14.4